Holen Sie sich die Stockscreener-App
33.58
1.32%
-0.45
Handel nachbörslich:
33.58
Schlusskurs vom Vortag:
$34.03
Offen:
$34.01
24-Stunden-Volumen:
399.29K
Relative Volume:
0.65
Marktkapitalisierung:
$1.94B
Einnahmen:
$32.87M
Nettoeinkommen (Verlust:
$674.31M
KGV:
2.956
EPS:
11.36
Netto-Cashflow:
$-330.11M
1W Leistung:
+5.46%
1M Leistung:
+12.05%
6M Leistung:
-43.06%
1J Leistung:
-31.23%
1-Tages-Spanne:
$33.22
$34.12
1-Wochen-Bereich:
$30.38
$34.70
52-Wochen-Spanne:
$23.41
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Firmenname
Agios Pharmaceuticals Inc
Sektor
Branche
Telefon
617-649-8600
Adresse
88 SIDNEY STREET, CAMBRIDGE, MA
Vergleichen Sie AGIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
33.58 | 1.84B | 32.87M | 674.31M | -330.11M | 11.36 |
|
ONC
Beone Medicines Ltd Adr
|
257.00 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.82 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.282 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
85.54 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
483.07 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-27 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-17 | Hochstufung | Goldman | Sell → Neutral |
| 2022-07-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Equal Weight |
| 2019-11-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-02-15 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-04-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-02-15 | Bestätigt | Needham | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-10 | Bestätigt | Needham | Buy |
| 2017-08-08 | Bestätigt | SunTrust | Buy |
| 2017-08-02 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Herabstufung | Janney | Buy → Neutral |
| 2017-01-17 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Eingeleitet | Needham | Buy |
| 2016-06-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Bestätigt | SunTrust | Buy |
Alle ansehen
Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten
Nuveen Asset Management LLC Cuts Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Ameriprise Financial Inc. Sells 34,140 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
When the Price of (AGIO) Talks, People Listen - news.stocktradersdaily.com
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025 | AGIO Stock News - GuruFocus
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025 - The Manila Times
Agios Pharmaceuticals Showcases Rare Disease Breakthroughs at Goldman Sachs Healthcare Conference - Stock Titan
BNP Paribas Financial Markets Sells 2,242 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
What is Zacks Research’s Estimate for AGIO Q2 Earnings? - Defense World
Agios Pharmaceuticals’ SWOT analysis: promising drug pipeline drives stock outlook By Investing.com - Investing.com South Africa
Agios Pharmaceuticals’ SWOT analysis: promising drug pipeline drives stock outlook - Investing.com Canada
Bank of America Corp DE Raises Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded to Sell Rating by StockNews.com - Defense World
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates - MSN
Analysts Update Their Estimates For Agios Pharmaceuticals Inc - Stocksregister
Agios pharmaceuticals outlines key catalysts for PYRUKYND pipeline in 2025 - MSN
Agios Pharma (AGIO) Gets a Buy from Bank of America Securities - The Globe and Mail
Beta thalassemia Market: Epidemiology, Therapies, Companies, - openPR.com
Sickle cell disease Market: Epidemiology, Therapies, - openPR.com
Agios Pharmaceuticals at Bank of America 2025 Healthcare Conference: Strategic Pipeline Advances - Investing.com Canada
Agios to Highlight Pyruvate Kinase Activation Portfolio with New - GuruFocus
Agios Pharmaceuticals (AGIO) Highlights Promising Data at EHA 20 - GuruFocus
Agios Pharmaceuticals (AGIO) Highlights Promising Data at EHA 2025 | AGIO Stock News - GuruFocus
Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress - The Manila Times
New Phase 3 Trial Data: Agios Blood Disorder Treatment Shows Promise in Children and Adults with Rare Diseases - Stock Titan
Northern Trust Corp Purchases 5,372 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Relapsed or Refractory Myelodysplastic Syndrome Pipeline - openPR.com
Cantor Fitzgerald maintains AGIOS stock with Overweight rating By Investing.com - Investing.com Canada
Top-line data from Phase 3 trial of mitapivat expected this year - Sickle Cell Disease News
Brokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Target Price at $56.00 - Defense World
Trading (AGIO) With Integrated Risk Controls - news.stocktradersdaily.com
Agios Pharmaceuticals (NASDAQ:AGIO) Stock Rating Upgraded by StockNews.com - Defense World
Agios to Present at the 2025 RBC Capital Markets Global Healthca - GuruFocus
Agios Pharmaceuticals' (NASDAQ:AGIO) Attractive Earnings Are Not All Good News For Shareholders - Yahoo Finance
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 | AGIO Stock News - GuruFocus
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 - The Manila Times
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Encourages AGIO Shareholders to Contact the Firm - ACCESS Newswire
Alpha Thalassemia Market Trends, Growth Forecast & Treatment - openPR.com
Scotiabank Issues Pessimistic Forecast for Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price - Defense World
Envestnet Asset Management Inc. Boosts Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insi - GuruFocus
Agios Pharmaceuticals (AGIO) Price Target Adjusted by Scotiabank - GuruFocus
Agios Pharmaceuticals (AGIO) Price Target Adjusted by Scotiabank Analyst | AGIO Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates - Barchart.com
Scotiabank cuts Agios Pharma stock target to $71, keeps outperform rating - Investing.com UK
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 | AGIO Stock News - GuruFocus
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 - The Manila Times
Agios to Reveal Latest Rare Disease Therapeutic Advances at Major BofA Healthcare Conference - Stock Titan
Agios Pharmaceuticals Inc Reports Q1 2025 EPS of -$1.55, Beating - GuruFocus
Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance
AGIO Receives Price Target Adjustment from Scotiabank | AGIO Stock News - GuruFocus
Finanzdaten der Agios Pharmaceuticals Inc-Aktie (AGIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Agios Pharmaceuticals Inc-Aktie (AGIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| FOUSE JACQUALYN A | Director |
Apr 10 '25 |
Sale |
25.90 |
7,497 |
194,172 |
149,220 |
0.86%
1.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):